問題 › 次にどこへ投資すべきか › HealthTech & Digital Health
次のリスク契約が締結されるとき、資本配分は誤ります。営業サイクルが、契約の成果率と帰属成果が持続可能かどうかを確認できる期間より短いためです。 デジタルヘルス企業には特有の制約があります。成果リスクを負う契約が、企業がそのリスクを負えるかどうかを判断できる期間より早く締結される点です。12か月の測定期間に対し、営業サイクルは11か月です。この点が価格に反映されない限り、成果連動型収益シェアは帰属不能な理由で動き続け、事業別リターンをめぐる議論は意見の域を出ません。
次のリスク契約が締結されるとき、資本配分は誤ります。営業サイクルが、契約の成果率と帰属成果が持続可能かどうかを確認できる期間より短いためです。 デジタルヘルス企業には特有の制約があります。成果リスクを負う契約が、企業がそのリスクを負えるかどうかを判断できる期間より早く締結される点です。12か月の測定期間に対し、営業サイクルは11か月です。この点が価格に反映されない限り、成果連動型収益シェアは帰属不能な理由で動き続け、事業別リターンをめぐる議論は意見の域を出ません。
ほとんどのデジタルヘルス企業は、過去の実績と社内主張に基づいて配分を決めます。前回の契約を獲得したプログラムが次の予算増分を受け、PMPM拡大の主張が強いチームが資金を得ます。いずれも、どの事業が次の加入者の粗利益率を改善するかという判断とは無関係です。
有効な分析は、各事業を2つの観点で順位付けします。成果連動型収益シェアと成果率で測った増分投資のリターン、およびロゴの解約と12か月の測定期間を考慮したときのリターンの持続性です。成果率を速く引き上げるが営業サイクル内でロゴを失う事業と、更新を通じて帰属成果を安定させる事業は、別の選択肢です。
出力は予算配分ではなく、停止条件付きの順序であるべきです。最初にどの事業を選び、その中で次の1ドルを何に充てるか、そしてその順序が誤りであることを示す成果率またはロゴ解約の変化は何か。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 予算は前年のPMPM目標に一定割合を加えたもので、現在の成果連動型収益シェアの実績に基づく再計算がありません。
✓ 誰も、成果率と粗利益率を組み合わせて増分投資のリターンで進行中のプログラムを順位付けできません。
✓ 投資判断は、解約と利益率の算出ではなく、次のロゴの規模や帰属成果の戦略的重要性で正当化されます。
通常、事態を悪化させる対応です。 社内の均衡を保つためにプログラムへ均等に資本を配分すること。これにより、測定期間内で成果率と成果連動型収益シェアが複利効果を発揮する事業への資金が不足します。
It is for you if you run or finance a digital health company and budgets are set by last year plus a percentage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Reduce downside exposure from $7.1M outcomes shortfall to $4.2M while maintaining upside participation in 34 health-plan contracts.
The leak it closes. $2.9M gross profit protected annually through downside cap (difference between $7.1M shortfall at 38% vs $4.2M shortfall at 25%)
The assumption it rests on. Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate — the engine put the probability at 0.7.
| Investment required | $0 incremental — policy change executed by existing legal, finance, and account management teams within current $14M annual burn |
| Expected return | 5.2× on zero incremental investment — derived from $4.2M FY2026 bookings protected relative to status-quo downside exposure |
| Revenue, year 1 | $57.8M ARR (25% at-risk share = $15.5M at-risk revenue vs $23.6M status quo) |
| Revenue, year 2 | $61.4M ARR (assuming 80% contract renewal at 25% cap) |
| Revenue, year 3 | $68.2M ARR (assuming 85% renewal and 10% PMPM stabilization) |
| Exit criteria | Abandon this move if >3 of 8 Q4 2026 contract renewals demand >15% PMPM reduction to accept 25% cap, OR if outcome-prediction accuracy falls below 70% on 10k cohort by Month 9; pivot to fixed-fee PMPM model with optional 15% upside sharing only |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
持続性を明示的に価格化します。減衰するリターンには半減期を明記します。各選択肢に半減期を付与すれば、異なる時間軸の選択肢を好みの問題ではなく比較可能なものにできます。
通常は強い部分です。限界1ドルがそこで複利を生むためです。弱い部分の修正は、それが強い部分の制約条件になっている場合に限り価値があります。
可逆性で判断します。2つの選択肢のリターンが近い場合、停止可能な方を選びます。得られる情報の価値が推定値の差を上回るためです。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית